A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticosteroids and rituximab, which have limitations including poor tolerance and incomplete responses. Physicians are optimistic about late-stage pipeline drugs like Sanofi's rilzabrutinib and Johnson & Johnson's niopcalimab, which could offer durable, steroid-sparing options and potentially redefine third-line treatment. These novel therapies may first establish themselves in refractory cases but could move earlier in treatment if proven effective and safe.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
